Background To evaluate the efficacy of intravitreal triamcinolone acetonide injection on persistent macular oedema in branch retinal vein occlusion that fails to respond to previous laser photocoagulation. Material and methods A total of 19 eyes of 19 patients with persistent macular oedema due to branch retinal vein occlusion were treated with 8 mg/0.2 ml of intravitreal triamcinolone acetonide injection. The main outcome measures included best-corrected visual acuity, intraocular pressure, and macular oedema map values of Heidelberg Retinal Tomograph II (HRT II) before and after intravitreal triamcinolone injection. Results The mean follow-up time was 6.271.0 months. The mean baseline bestcorrected logarithm of minimal angle of resolution (LogMAR) value for visual acuities of the patients before intravitreal triamcinolone injection was 1.0170.16. After treatment, it was 0.5570.22 at the 1-month, 0.5670.22 at 3-month, and 0.6270.22 at the last visits and the differences were statistically significant when compared with baseline values (for each, Po0.001). The mean oedema map values on HRT II significantly decreased by 28.5% at 1-month, 23.8% at 3-month, and 23.8% at the last visit when compared with preinjection values (for each, Po0.001). Intraocular pressure elevation exceeding 21 mmHg was observed in 26.3% of eyes at 1-month, 15.7% at 3-month, and 5.2% at the last visit, but was controlled with topical antiglaucomatous medications in all eyes.
Introduction
Branch retinal vein occlusion (BRVO) is a common retinal disease causing visual loss due to macular oedema, macular nonperfusion, and vitreous haemorrhage between the ages of 60 and 70 years. It is associated with various risk factors including systemic hypertension, diabetes mellitus, high body mass index, and inflammatory or thrombophilic conditions that may lead to retinal endothelial vascular damage. [1] [2] [3] When fluorescein angiography demonstrates macular oedema with cystoid involvement of the fovea, but no capillary nonperfusion, it is presumed that the macular oedema is the cause of vision loss. 4 Macular grid laser photocoagulation has been shown to be effective in the treatment of macular oedema in a large prospective multicentre randomized clinical trial of BVOS. 5 After 3 years of followup, 63% of laser-treated eyes gained two or more lines of vision, compared to 36% of untreated eyes. However, some eyes may be resistant to grid laser photocoagulation. Moreover, eyes with diffuse macular oedema have a particularly poor prognosis despite laser treatment. 6 Therefore, the failure of laser photocoagulation in these eyes has prompted interest in other treatment modalities including laser-induced chorioretinal anastomosis, 7 vitrectomy, and arteriovenous decompression. 8, 9 Triamcinolone acetonide is a safe agent for intravitreal injection in vitrectomized and nonvitrectomized eyes. 10, 11 Intravitreal triamcinolone acetonide (IVTA) injection has recently been reported to be effective in macular oedema of various aetiologies. [12] [13] [14] [15] Although there are few reports regarding the treatment of macular oedema in central retinal vein occlusion (CRVO) with IVTA injection, [16] [17] [18] [19] there has been no previous study evaluating the efficacy of IVTA application on chronic macular oedema in BRVO that persists despite laser photocoagulation.
Therefore, the present study investigated the efficacy of IVTA injection in the treatment of persistent macular oedema in patients with BRVO.
Patients and methods
A total of 19 eyes of 19 patients (11 men and eight women) with persistent macular oedema due to BRVO were included in the present study. The mean age of the patients was 64.376.0 years. All patients had persistent macular oedema with hyperfluorescent leakage on fundus fluorescein angiography for at least 8 months, and had received grid laser photocoagulation before IVTA injection. A detailed history of medication was obtained, and the patients were excluded from the study if they had diabetes mellitus, severe renal dysfunction, nephrotic syndrome, dysproteinaemias, or were receiving vasoactive drugs or antioxidant (Figure 1 ).
Intravitreal injection of triamcinolone acetonide (8 mg/ 0.2 ml) was offered to treat persistent macular oedema. All patients were fully informed about the character of the treatment and informed consent was obtained from each patient. The study followed the tenets of Declaration of Helsinki. Baseline parameters were documented including best-corrected visual acuity, macular oedema map values of Heidelberg Retinal Tomograph II (HRT II) (Heidelberg Engineering GmbH, Heidelberg, Germany), and intraocular pressures. Bestcorrected visual acuity for each eye was ascertained before IVTA applications, and then all eyes were tested with the same correction throughout the follow-up period. The average visual acuity was computed by converting the value to the logarithm of minimal angle of resolution (LogMAR) equivalent, and taking the average of the LogMAR values as described by Holladay. 20 All statistical calculations were performed using LogMAR values for visual acuity. IVTA injections were performed by the same surgeon (AÖ ) under topical anaesthesia. The standard, commercially available preparation of triamcinolone acetonide (Kenacort-A, Bristol-Myers Squibb, NY, USA) in a concentration of 40 mg/ml was used. First, the eye was anaesthetized with topical instillation of proparacaine hydrochloride 0.5% and lidocaine 4%. The lid was prepped with povidone-iodine 5% applied directly to the eye, and triamcinolone acetonide was injected transconjunctivally after a paracentesis had been performed to decrease the volume of the globe. A cotton-tipped applicator was applied at the injection site immediately after the needle was removed to prevent drug egression from the needle track. Indirect ophthalmoscopy was used to confirm proper intravitreal localization of the suspension and perfusion of the optic nerve head. Topical ciprofloxacin drops were applied, and the IOP was measured 5 min afterwards. The eyes were examined after 1 week and every 4 weeks thereafter unless IOP spikes required more frequent examinations. IOPs were measured using a Goldmann applanation tonometer. Response to the treatment was monitored by visual acuity assessment, HRT II, and FFA. Potential corticosteroid-induced and injection-related complications were also recorded, if present.
The analysis of macula oedema was performed using the HRT II Macula Oedema Module. Oedema map value of HRT II was used to evaluate the changes at the macula after IVTA injection. The HRT II is a confocal laser scanning system that requires a series of optical section images at different locations of the focal plane. Technical details of the instrument have been described elsewhere. 21 The patient's macula was focused on the monitor screen by adjusting the location of the focal plane, the best focus being directly related to the subject's refractive error. The 670 nm wavelength diode laser was used to image the macula using a 151 Â 151 field of view. The total scan depth was adjusted according to the thickness of the structure to be analysed from 0.50 to 4.00 mm.
Statistical analysis
Results are presented as mean7SD. Statistical evaluation of the data was performed with two-way ANOVA. A difference was considered statistically significant when the P-value was lower than 0.05.
Results
All patients had persistent macular oedema involving the centre of the macula with a mean duration of 12.673.0 months (range; 8-19 months). Before intravitreal triamcinolone injection, all eyes had received an average of 1.3 laser sessions (range; 1-3 sessions). Pre-and posttreatment visual acuities are presented in Table 1 . The mean visual acuity improved significantly from 1.0170.16 at baseline to a maximum of 0.5570.22 LogMAR during follow-up. There were statistically significant differences in mean visual acuities after IVTA injection when compared with pretreatment values (for each, Po0.001). After intravitreal injection, visual acuity increased in 17 of 19 eyes and remained unchanged in the remaining two eyes. Maximal increase in visual acuity was observed between the 1st and 3rd months after intravitreal injection.
The mean oedema map value before IVTA injection was 2.170.2 (range; 1.7-2.7). After IVTA injections, it was 1.570.4 (range; 1.1-1.9), 1.670.3 (range; 1.0-2.1), and 1.670.4 (range; 1.1-2.3) at the 1-, 3-month, and last visit follow-up examinations, respectively. All eyes showed a reduction in macular oedema map value after IVTA injection. The mean reduction of oedema map values at 1-, 3-month, and last visit follow-up examinations was 28.5, 23.8, and 23.8%, respectively and the differences were statistically significant when compared with preinjection values (for each, Po0.001).
IOPs of the patients before and after intravitreal injections are shown in Table 1 . The mean IOP before 
Discussion
Macular oedema is a common cause of visual loss in patients with BRVO. A disruption of the inner bloodretinal barrier is due to elevation of distal intravascular pressures, and is often associated with significant hyperfluorescent leakage and a relatively poor prognosis. This vasogenic oedema is less likely to resolve spontaneously and laser photocoagulation should be considered if macular oedema persists. 22 The Branch Retinal Vein Occlusion Study evaluated the effectiveness of grid laser photocoagulation in reducing macular oedema. They have reported that treated eyes were twice as likely to improve two or more lines with an achievement of a visual acuity of 20/40 or better when compared with untreated control eyes. 5 Another approach for the treatment of macular oedema is to reroute the blood flow by a laser-induced chorioretinal venous anastomosis, but this technique may be associated with some complications, including fibrovascular proliferation, haemorrhage, and tractional retinal detachment. 23 Vitrectomy with mechanical separation of the arteriovenous sheath at the site of occlusion is another option in the treatment of macular oedema in patients with BRVO. 8, 9 Intravitreal tissue plasminogen activator administration has also been tested with mixed results. 24 Inflammatory mediators are implicated in the pathogenesis of macular oedema. Corticosteroids inhibit phospholipase A 2 and subsequent release of arachidonic acid, which is the precursor of prostaglandins and leukotrienes. Corticosteroids also downregulate the production of vascular endothelial growth factor, a known permeability factor. 25 Triamcinolone acetonide is a corticosteroid suspension with no known retinal toxicity when injected intravitreally and has been shown to reduce breakdown of the inner blood-retinal barrier. 26 Subtenon, retrobulbar, or topical applications of corticosteroids are insufficient to deliver adequate drug levels to the vitreous and retina. Although oral prednisone delivers effective levels of intraocular steroids, systemic side effects are present that outweigh the benefit. Maximal bioavailability of triamcinolone is only possible if it is delivered intravitreally. In other words, direct intraocular injection of steroids delivers the desired drug to its target tissue in the most direct fashion without extraocular side effects. Animal studies have shown that triamcinolone crystals can be visualized in the vitreous humour for 23-41 days after the injection. 27 Although all eyes in our study were treated with grid laser photocoagulation before IVTA injection, there was no corresponding improvement in their visual acuity and macular oedema did not resolve with demonstrated leakage on fundus fluorescein angiography. The results of our study showed that IVTA application was effective in the treatment of persistent macular oedema in BRVO unresponsive to previous laser photocoagulation. Visual acuity increased in the majority of the cases. In addition, quantitative measurement of oedema map value by HRT II showed a reduction in all eyes at the follow-up examinations.
There are some favourable results in a limited number of patients evaluating the efficacy of triamcinolone on macular oedema in CRVO. [16] [17] [18] [19] As macular oedema occurs with the same mechanism both in central and BRVO, we can compare our results with those in CRVO. After IVTA injection, Jonas et al 16 reported an increase in the visual acuity of a patient with cystoid macular oedema due to CRVO. Bynoe et al 17 treated two patients with unilateral CRVO and reported that one patient recovered eight lines of visual acuity whereas the other recovered 11 lines. Greenberg et al 18 demonstrated that the visual acuity of a patient with macular oedema due to CRVO improved from counting fingers to 20/80 at 6 weeks after intravitreal injection. Our results were compatible with those mentioned above.
This present study has some differences from previous studies. First, it has a large case series when compared with the previous studies. Second, the dosage of IVTA was injected as treatment of macular oedema. Third, macular oedema was evaluated by HRT II before and after IVTA injection, and reduction in oedema map values was demonstrated as the efficacy of IVTA application. However, our study has two limitations. First, there was no control group, but it can be argued that the enrolled eyes serve as their own controls because the pre-and post-treatment visual acuities and oedema map values of the same patients were compared. Second, the follow-up time is relatively short, but visual and anatomic responses were clear during the follow-up time.
In conclusion, IVTA application is a safe and effective approach for the treatment of persistent macular oedema as a result of BRVO unresponsive to laser photocoagulation. The effects occur immediately with a rapid resolution of macular oedema and the short-term results are very promising. However, further studies are needed to obtain the long-term results of such an application.
